Abstract
Background: Benign Prostatic Hyperplasia (BPH) is the most common urological cause of urinary obstruction, affecting men above 50 years of age. Medical therapy used for managing BPH includes various medical regimes, including 5-alpha reductase inhibitors (5ARI), namely Dutasteride and more. The study aimed to evaluate the efficacy of four weeks' prior treatment with dutasteride on per-operative blood loss in patients of BPH undergoing transurethral resection of the prostate.
 Methodology: A prospective observational study was conducted from January to December 2019 at the Kidney Centre, Karachi, Pakistan. A total of 64 patients were included and divided into two groups. Group A patients were those who had been taking dutasteride (0.5 mg/day) for four weeks or more before surgery, and group B patients were not taking dutasteride drug before surgery. All patients underwent standard TURP, and the intra-operative blood loss was calculated. The collected data was analyzed using SPSS version 22.0.
 Results: In our study, there was a significantly less hemoglobin drop (1.2 gm vs. 2.2 gm) during prostate surgery in patients using dutasteride than those who were not using dutasteride.
 Conclusion: This study has revealed that the use of dutasteride four weeks before surgery significantly reduces intra-operative bleeding.
Highlights
Dihydrotestosterone (DHT) has an obligatory role in the differentiation of the prostate during gestation and development of benign prostatic hyperplasia (BPH) in later years[1]
Clinical Benign Prostatic Hyperplasia (BPH) is explained as hyperplasia of the prostate gland that leads to symptomatic or asymptomatic bladder outlet obstruction irrespective of the size of the prostate gland[2]
It is one of the commonest causes of lower urinary tract symptoms (LUTS) in men affecting the quality of life as a progressive disease of ageing due to the prostate gland's noncancerous proliferation and imbalance between the stroma and epithelium[3]
Summary
Dihydrotestosterone (DHT) has an obligatory role in the differentiation of the prostate during gestation and development of benign prostatic hyperplasia (BPH) in later years[1]. Clinical BPH is explained as hyperplasia of the prostate gland that leads to symptomatic or asymptomatic bladder outlet obstruction irrespective of the size of the prostate gland[2] It is one of the commonest causes of lower urinary tract symptoms (LUTS) in men affecting the quality of life as a progressive disease of ageing due to the prostate gland's noncancerous proliferation and imbalance between the stroma and epithelium[3]. This study aimed to evaluate the efficacy of four weeks' prior treatment with dutasteride on per-operative blood loss in patients of BPH undergoing transurethral resection of the prostate (TURP). Conclusion: This study has revealed that the use of dutasteride four weeks before surgery significantly reduces intra-operative bleeding
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Endorsing Health Science Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
